Kalaris Therapeutics, Inc.
KLRS
$3.08
$0.5220.31%
NASDAQ
06/30/2025 | 03/31/2025 | ||||
---|---|---|---|---|---|
Net Income | -100.88% | -199.27% | |||
Total Depreciation and Amortization | -- | -- | |||
Total Amortization of Deferred Charges | -100.00% | -76.54% | |||
Total Other Non-Cash Items | 15.88% | 31.95% | |||
Change in Net Operating Assets | -934.88% | 213.01% | |||
Cash from Operations | -215.76% | -64.59% | |||
Capital Expenditure | -- | -- | |||
Sale of Property, Plant, and Equipment | -- | -- | |||
Cash Acquisitions | -- | -- | |||
Divestitures | -- | -- | |||
Other Investing Activities | -- | -- | |||
Cash from Investing | -- | -- | |||
Total Debt Issued | -100.00% | 50.21% | |||
Total Debt Repaid | -- | -- | |||
Issuance of Common Stock | -- | -- | |||
Repurchase of Common Stock | -- | -- | |||
Issuance of Preferred Stock | -- | -- | |||
Repurchase of Preferred Stock | -- | -- | |||
Total Dividends Paid | -- | -- | |||
Other Financing Activities | 100.00% | 1,995,440.00% | |||
Cash from Financing | -100.00% | 1,530.45% | |||
Foreign Exchange rate Adjustments | -- | -- | |||
Miscellaneous Cash Flow Adjustments | -- | -- | |||
Net Change in Cash | -1,339.03% | 4,750.63% | |||